Key facts
- It has raised $5.4M; the latest was Seed Round ($5.4M) in Jan 2026.
- Notable investors include Electric Capital, Tarsadia Investments, Wisdom Ventures Fund.
- Status: Privately Held (backing).
Leadership
- John MummChief Scientific Officer
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for ChronicleBio
- ·The full record, as it builds
Funding rounds
No funding rounds for ChronicleBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ChronicleBio
Developer of a decentralized research ecosystem designed to advance the understanding and treatment of complex neuroimmune disorders. The company's data-driven healthcare platform offers a comprehensive platform that integrates multi-omic data, real-time symptom tracking, and a secure biobank, enabling researchers and clinicians to create personalized diagnostics and therapeutic strategies to help diagnose and treat patients with chronic illnesses.
- Sector
- Healthcare
- HQ
- West Valley City, UT, United States
- Founded
- 2025
- Employees
- 9
- Website
- chroniclebio.com/
- Ownership
- Privately Held (backing)
ChronicleBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ChronicleBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ChronicleBio in its N-PORT filings yet. We sweep new filings monthly.